Merck to create separate cancer business to offset Keytruda patent loss
Feb 23 (Reuters) - Merck said on Monday it will split its human-health business into two divisions, separating its blockbuster cancer franchise led by Keytruda from its non-oncology medicines.
The shake-up comes as the drugmaker braces for the looming loss of exclusivity on Keytruda, which... Read More.


